ABSTRACT
Introduction According to the National Oncological Plan 2023-2027 on the importance of multidisciplinary and interactive e-learning training, the Italian Melanoma Intergroup (IMI) has developed MelaMEd (Melanoma Multimedia Education), a national project for general practitioners (GPs) on the prevention and detection of cutaneous melanoma through an online platform and an online course. MelaMEd enables participants to (1) recognize skin lesions that require specialist dermatological assessment, (2) select patients at high risk of melanoma and (3) be informed of the diagnosis and treatment pathway of patients with melanoma.
Methods A free online platform and online course were developed and launched in June 2022. Before starting the course, enrolled participants fill out a pre-training questionnaire concerning the basic knowledge of the disease and the recognition and management of suspicious lesions. After the course, participants will fill out the same questionnaire again. The online course will end in December 2023. Here we present a preliminary analysis of the pre-training results (January 2023-July 2023). The data have been analyzed descriptively.
Results So far, five healthcare centers have participated in the project for a total of 1320 participants. Of these, 298 compiled the pre-training questionnaire. Forty-seven percent of them were aged <40 years. Respondents were almost divided between GPs (47%) and resident GPs (48%). Among the theoretical questions, the “ABCDE” rule and “ugly duckling” sign are well known (96% and 91% of correct answers, respectively), but a lower percentage (68%) of respondents knows the “EFG” rule for the recognition of nodular melanomas and the statement of Breslow thickness (29%).
Regarding the series of clinical images of pigmented skin lesions and their management, the percentages rate of accuracy varied from 33% to 87%: melanoma (5 cases) ranges from 36% to 71%, melanocytic nevi (3 cases) from 33% to 84%, whereas the percentages rate of referral for dermatological evaluation varied from 44% to 99%. Melanoma cases referred to dermatologist ranges from 67% to 99%.
Conclusions This preliminary analysis on pre-training questionnaire mainly showed a lack of knowledge of the two major points of melanoma diagnosis (EFG) and management (Breslow thickness), as well as a low rate of participants. We will compare the proportions of correct answers to the questionnaires before and after the course once available.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partly supported thanks to the contribution of Ricerca Corrente by the Italian Ministry of Health within the research line Appropriateness, outcomes, drug value and organizational models for the continuity of diagnostic-therapeutic pathways in oncology.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study design complied with the Declaration of Helsinki ethical standards and was approved by the Ethics Committee at the Romagna Cancer Institute (ID: IRST100.37; IRST identifier codes: L4P3037, wfn.27L4). The study was approved by the Scientific Committee of the Italian Melanoma Intergroup (IMI).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of interest: The authors declare no potential conflict of interest.
Ethics approval: The study design complied with the Declaration of Helsinki ethical standards and was approved by the Ethics Committee at the Romagna Cancer Institute (ID: IRST100.37; IRST identifier codes: L4P3037, wfn.27L4). The study was approved by the Scientific Committee of the Italian Melanoma Intergroup (IMI).
Funding This work was partly supported thanks to the contribution of Ricerca Corrente by the Italian Ministry of Health within the research line “Appropriateness, outcomes, drug value and organizational models for the continuity of diagnostic-therapeutic pathways in oncology”.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
